Clinical Trial Update: Study of NEO-201 in Solid Tumors Expansion Cohorts [Phase 1, Phase 2]

View source ↗

Summary

Precision Biologics is expanding cohorts in a Phase 1/2 study of NEO-201 in solid tumors, including non-small cell lung cancer, head and neck squamous cell carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Uterine Cancer

Drugs mentioned

• NEO-201

Snippet

Sponsor: Precision Biologics, Inc | Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING